Who We Are—Our Board of Directors

At Inspiration, we have a dedicated Board of Directors who all share our aspiration to redefine hemophilia treatment. Our dream is to help make it easier for people with hemophilia to live the extraordinary lives that they aspire to. The main focus of our company is to advance the treatment of hemophilia for everyone and help them make their dreams more achievable.

Mr Taylor is Co-founder and Chairman of Inspiration Biopharmaceuticals as well as Chairman, CEO, and CIO of FX Concepts, an investment management company with $12.2 billion in assets. He has over 35 years of experience in the foreign exchange and related fixed-income markets. Prior to founding FX Concepts, Mr Taylor was a Vice President at Citibank, where he headed the bank's foreign exchange marketing and advisory services. He has been actively involved with the hemophilia community, both as a patient advocate and in the search for improved factor therapies. He was a founder of US Transgenics (currently American Integrated Biologics) and of The Coalition for Hemophilia B, and is the recipient of two issued US patents for coagulation protein drug delivery. Mr Taylor is a magna cum laude graduate of Princeton University.

Mr Martin is Co-Founder and Vice Chairman of Inspiration Biopharmaceuticals. He spent 22 years with Martin Resource Management Corporation (MRMC), a Texas-based energy company with over $1 billion in revenue, where he served on the Board of Directors and was an Executive Vice President of the company. During his tenure, Mr Martin led an initial public offering of Martin Midstream Partners, LP (NASDAQ:MMLP), and founded and/or managed various business lines within MRMC. Mr Martin either currently serves or has previously served as a member of the board of Martin Midstream Partners, LP (NASDAQ:MMLP), MRMC, Cardinal Gas Storage Partners, East Texas Mack, Inc, American Waterway Operators, and the University of Arkansas Walton Business School (Advisory Board). He is a graduate of the University of Arkansas.

Mr Evans-Freke is Co-founder and Managing General Partner of Celtic Therapeutics Management, L.L.L.P., and Co-founder and Managing Principal of Celtic Pharma Management, L.P., both global private equity firms focused on the pharmaceutical industry. Mr Evans-Freke was also a Founder or Co-founder of Fibrogen, Inc., Royalty Pharma AG, Selectide Corporation, and SUGEN. During the 1980s, he was lead investment banker to Genentech, Amgen, Centocor, and a number of other leading biotech companies. He structured and placed over $500 million of highly successful research and development partnership financing and he served on the development boards of those companies. He currently serves on the boards of Elbion AG, Montier Asset Management, Ltd., and International Bioscience Managers, Ltd. Mr Evans-Freke holds a law degree from Cambridge University.

Mr Frankel is the Founder and Managing Partner of Frankel Group, a management consulting firm that has served the life-science industry and related segments since 1993. Previously, he was President of SJ Weinstein Associates, a healthcare marketing strategy and advertising firm, where he formulated marketing and communications strategies for leading life-science companies. Mr Frankel's earlier experience included strategic planning for Pfizer Pharmaceuticals, as well as senior marketing positions at Pfizer targeting the anti-infective, multisource pharmaceutical, and diagnostic markets. In addition, he was an investment research officer for life-science investments at Citibank. Mr Frankel holds an MBA degree from The Wharton School of the University of Pennsylvania and a BS degree in engineering from Rutgers University.

Mr Butler, Chief Executive Officer of Inspiration Biopharmaceuticals, has more than 20 years of experience commercializing innovative therapies, most recently leading businesses that serve rare disease patient populations. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College. He currently serves on the board of the American Kidney Fund and the Boys and Girls Club of Metrowest.

Mr Picot is Vice President, Global Regulatory Affairs, of Ipsen (Euronext:IPN; ADR:IPSEY), a global biopharmaceutical group. Prior to joining Ipsen, he held positions of increasing responsibility in the Regulatory Affairs group at Bristol-Myers Squibb as Vice President, Global Regulatory Sciences for Europe, the Middle East, and Africa. Earlier, Mr Picot was responsible for drug development at Laboratoires Fournier. He began his career within Merck, Sharpe & Dohme's US Regulatory Affairs Group. Mr Picot holds a PhD in pharmaceutical sciences and an MS in drug law from the University of Paris.

Ms Dawes is the President and Founder of Knowledgeable Decisions, LLC, a management consulting firm. She served 10 years at Pfizer, where she gained increasing responsibility in product management, development, and strategy, leading to her position as Vice President, Marketing, Pratt Division. Ms Dawes then joined Genetics Institute (GI) where, as Vice President, Commercial Operations, she and her team successfully launched two products including BeneFIX^® for factor IX replacement in hemophilia. When GI was acquired by Wyeth, Ms Dawes moved to the new parent company as Senior Vice President, Global Strategic Marketing. In 1998, she joined Bayer Corporation as SVP/Division Head for the company's $2 billion US Pharmaceuticals Division. Ms Dawes holds an MBA with a concentration in marketing & corporate strategy from Harvard University and an MA and BA from Simmons College.